ENOVIS CORP
ENOVNYSETrading Snapshot
- Day Range
- $21.46 β $22.29
- 52-Week Range
- $16.70 β $33.13
- Volume (shares)
- 1,175,547
- Avg Volume (shares)
- β
- Shares Outstanding
- 57.7M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $2.25B
- Last Q Revenue
- $583M
- P/E Ratio
- -1.1
- P/S Ratio
- 0.6x
- EPS (TTM)
- $-19.13
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β2.7%
ENOVIS CORP
ENOVAbout ENOVIS CORP
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionalsβincluding orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainersβwho treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
Dallas, TX, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Enovisβ’ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss

electroCore (NASDAQ:ECOR) and Enovis (NYSE:ENOV) Head-To-Head Comparison
electroCore (NASDAQ: ECOR - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the stren

Critical Survey: Enovis (NYSE:ENOV) vs. Nexalin Technology (NASDAQ:NXL)
Nexalin Technology (NASDAQ: NXL - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the

Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
Company expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry ROSEMONT, Ill., Sept. 22, 2026 /PRNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) announc

Enovis (NYSE:ENOV) Hits New 52-Week Low β Whatβs Next?
Enovis Corporation (NYSE: ENOV - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $17.30 and last traded at $17.9220, with a volume of 2658431 share

Insider at Medical Device Maker Buys More Than 7,500 Shares
Engert's $150,000 purchase represents a 14% increase to his direct holdings, signaling confidence despite stock's -37% one-year decline.